| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Zhongjin Irradiation Incorporated Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.47 |
| 52 Week High | CN¥18.94 |
| 52 Week Low | CN¥10.18 |
| Beta | 0.44 |
| 11 Month Change | 4.42% |
| 3 Month Change | -17.11% |
| 1 Year Change | -24.79% |
| 33 Year Change | -32.65% |
| 5 Year Change | n/a |
| Change since IPO | -61.18% |
Recent News & Updates
Shareholder Returns
| 300962 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | -3.5% | 1.7% | 0.1% |
| 1Y | -24.8% | -35.1% | -16.6% |
Return vs Industry: 300962 exceeded the CN Healthcare industry which returned -35.1% over the past year.
Return vs Market: 300962 underperformed the CN Market which returned -16.6% over the past year.
Price Volatility
| 300962 volatility | |
|---|---|
| 300962 Average Weekly Movement | 5.3% |
| Healthcare Industry Average Movement | 5.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in CN Market | 9.1% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 300962's share price has been volatile over the past 3 months.
Volatility Over Time: 300962's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 603 | Dongbo Zhang | www.zjfzgroup.com |
Zhongjin Irradiation Incorporated Company provides irradiation technology services in China. It offers irradiation sterilization services for medical and health care products, food, medicines, packaging materials, and other products; and irradiation modification services for polymer materials. The company was incorporated in 2003 and is based in Shenzhen, China.
Zhongjin Irradiation Incorporated Company Fundamentals Summary
| 300962 fundamental statistics | |
|---|---|
| Market cap | CN¥3.56b |
| Earnings (TTM) | CN¥108.77m |
| Revenue (TTM) | CN¥353.98m |
32.7x
P/E Ratio10.0x
P/S RatioIs 300962 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300962 income statement (TTM) | |
|---|---|
| Revenue | CN¥353.98m |
| Cost of Revenue | CN¥132.30m |
| Gross Profit | CN¥221.68m |
| Other Expenses | CN¥112.91m |
| Earnings | CN¥108.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 62.63% |
| Net Profit Margin | 30.73% |
| Debt/Equity Ratio | 0% |
How did 300962 perform over the long term?
See historical performance and comparison